Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Circulating tumor cells (CTCs) improve risk stratification according to the second revision of the international staging system (R2-ISS) and the ims-IMWG consensus genomic staging (CGS) in newly diagnosed multiple myeloma (NDMM): An analysis from the european CTC consortium.

View Full Paper
Ask AI
Bookmark
Share

Authors

DŽDavid ŽihalaGBGiuseppe BertugliaJKJonathan J. Keats

Discussion

Loading...

Member takes

Overview

Analysis identifies circulating tumor cells as independent biomarkers for risk stratification in newly diagnosed multiple myeloma patients, suggesting implications for therapy decisions.

Key Points

  • Circulating tumor cells serve as independent biomarkers for risk stratification in newly diagnosed multiple myeloma patients.
  • Prognostic model including circulating tumor cells improved progression-free survival assessment in the cohort analyzed.
  • Significant outcomes revealed circulating tumor cells' predictive value, indicating higher risks associated with their levels.
  • Findings highlight the potential integration of circulating tumor cells into existing risk stratification frameworks for myeloma.

Cite This Study

Žihala et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0dahttps://doi.org/10.1182/blood-2025-364
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Validation of the High-Risk Consensus Genomic Staging System in Newly Diagnosed Multiple Myeloma2025 · 1 citations
  2. 2Circulating tumor plasma cells as an independent prognostic marker in newly diagnosed multiple myeloma: Clinical correlation and immunophenotypic insights2025
  3. 3Biology of circulating tumor cells (CTCs) in multiple myeloma (MM): Comparative transcriptomic profiling reveals egression-associated changes related to CTC burden2025
  4. 4Absence of circulating tumor cells (CTCs) defines a subtype of multiple myeloma (MM) patients (Pts) with unique clinical and biological features2025 · 1 citations
  5. 5Quantification of circulating plasma cells at diagnosis can identify functional high risk multiple myeloma patients2025